Citalopram and escitalopram plasma drug and metabolite concentrations: genome‐wide associations

Aims Citalopram (CT) and escitalopram (S‐CT) are among the most widely prescribed selective serotonin reuptake inhibitors used to treat major depressive disorder (MDD). We applied a genome‐wide association study to identify genetic factors that contribute to variation in plasma concentrations of CT...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2014-08, Vol.78 (2), p.373-383
Hauptverfasser:	Ji, Yuan, Schaid, Daniel J., Desta, Zeruesenay, Kubo, Michiaki, Batzler, Anthony J., Snyder, Karen, Mushiroda, Taisei, Kamatani, Naoyuki, Ogburn, Evan, Hall‐Flavin, Daniel, Flockhart, David, Nakamura, Yusuke, Mrazek, David A., Weinshilboum, Richard M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Biotransformation citalopram Citalopram - blood Citalopram - metabolism Citalopram - therapeutic use Cytochrome P-450 CYP2C19 - genetics Cytochrome P-450 CYP2D6 - genetics Depressive Disorder, Major - drug therapy Depressive Disorder, Major - metabolism escitalopram Female Genome-Wide Association Study Humans major depressive disorder Male Middle Aged Molecular Sequence Data Pharmacogenetics plasma drug concentration Polymorphism, Single Nucleotide selective serotonin reuptake inhibitor Serotonin Uptake Inhibitors - blood Serotonin Uptake Inhibitors - metabolism Serotonin Uptake Inhibitors - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!